Leukemia, Acute Lymphoblastic Clinical Trial
Official title:
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia
Verified date | January 2020 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART19" cells) in adults with minimal residual disease (MRD) during upfront treatment for CD19+ acute lymphoblastic leukemia.
Status | Terminated |
Enrollment | 1 |
Est. completion date | December 12, 2018 |
Est. primary completion date | December 12, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with CD19+, B cell Acute Lymphoblastic Leukemia (B-ALL) who have 0.01%=MRD<10% during upfront treatment 2. Patients must be within 18 months of initial ALL diagnosis 3. Age =18 years 4. Adequate organ function defined as: 1. Creatinine = grade 2 2. ALT/AST =3x upper limit of normal range for age 3. Direct bilirubin =2.0 mg/dl 4. Adequate pulmonary function defined as = grade 2 dyspnea and = grade 2 hypoxia 5. Cardiac Left Ventricle Ejection Fraction (LVEF) = 40% confirmed by ECHO/MUGA 5. Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy. 6. Expression of CD19 on leukemic blasts demonstrated by flow cytometry or immunohistochemistry of bone marrow or peripheral blood 7. Adequate performance status defined as ECOG Performance Status 0 or 1 8. Provides written informed consent 9. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Exclusion Criteria: 1. Active, uncontrolled infection 2. Active hepatitis B or hepatitis C 3. HIV Infection 4. Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 2) 5. Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollment. 6. Pregnant or nursing (lactating) women 7. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Incidence of Conversion of Minimal Residual Disease (MRD) to <0.01% | The incidence of conversion of minimal residual disease (MRD) to <0.01% after CART19 therapy in patients with MRD+ ALL during upfront treatment | Day 28 | |
Secondary | Best Overall Survival (OS) | Overall survival (OS) is defined as the time from the date of the first CART19 infusion to the date of death due to any reason. | one year | |
Secondary | Duration of Remission (DOR) | Duration of remission (DOR) is defined as the duration from the date when the response criteria of CR or CRi is first met to the date of relapse or death due to ALL. | one year | |
Secondary | Relapse Free Survival (RFS) | Relapse free survival (RFS) is defined as the duration between the date when the response criteria of CR or CRi is first met to the date of relapse or death due to any cause. | one year | |
Secondary | Event Free Survival (EFS) | Event free survival (EFS) is defined as the time from start of the first CART19 infusion to the earliest of the following:
Death from any cause Relapse Treatment failure: Defined as no response in the study and discontinuation from the study due to any of the following reasons: Adverse event(s) Abnormal laboratory value(s) Abnormal test procedure results New cancer therapy (excluding HSCT when performed in CR or CRi) |
one year | |
Secondary | Percentage of Manufacturing Products That do Not Meet Release Criteria for Vector Transduction Efficiency, T Cell Product Purity, Viability, Sterility or Due to Tumor Contamination. | Percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility or due to tumor contamination. | prior to day 1 | |
Secondary | Safety and Tolerability of CART19: Frequency and Severity of Adverse Events, Including, But Not Limited to, Cytokine Release Syndrome (CRS) and Macrophage Activation Syndrome (MAS). | Frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS) and macrophage activation syndrome (MAS). | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT02360930 -
Vincristine PK and PD in the AYA Population Compared to Younger Children
|
N/A | |
Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
Not yet recruiting |
NCT06101381 -
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05440409 -
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
|
||
Completed |
NCT02393859 -
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 3 | |
Completed |
NCT05064787 -
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
|
N/A | |
Terminated |
NCT02435550 -
iCare for Cancer Patients
|
N/A | |
Completed |
NCT02799147 -
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT02580981 -
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
|
N/A | |
Recruiting |
NCT04307576 -
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
|
Phase 3 | |
Completed |
NCT04942730 -
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
|
Phase 2 | |
Terminated |
NCT01761682 -
Acute Lymphoblastic Leukemia Registry at Asan Medical Center
|
||
Completed |
NCT04327037 -
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
|
Phase 1 | |
Terminated |
NCT02349178 -
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
|
Phase 2 | |
Recruiting |
NCT04209244 -
Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT03911128 -
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
|
||
No longer available |
NCT00590915 -
Erwinase Master Treatment Protocol
|
N/A |